Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: A pilot patient study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 4, 2009, Pages 417-426

  Dewaraja, Yuni K ^a   Wilderman, Scott J ^a   Koral, Kenneth F ^a   Kaminski, Mark S ^a   Avram, Anca M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Patient specific dosimetry; Radioimmunotherapy; SPECT quantification; SPECT CT imaging; Tumor regression

Indexed keywords

IODINE 131; TOSITUMOMAB; TOSITUMOMAB I 131;

ACCURACY; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG HALF LIFE; FOLLICULAR LYMPHOMA; HUMAN; IMAGE RECONSTRUCTION; ISOTOPE LABELING; MONTE CARLO METHOD; PATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR REGRESSION; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, FOLLICULAR; PILOT PROJECTS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 69249150905     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0568     Document Type: Article

References (30)

1. Meredith R. Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response. Cancer Biother Radiopharm 2002;17:83.
2. 131I-tositumomab therapy as initial treatment for follicular lymphoma. NEJM 2005;352:441.
3. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med 1996;37:1970.
4. Eary JF, Pollard KR, Durack LD, et al. Post therapy imaging in high-dose 1-131 radioimmunotherapy patients. Med Phys 1994;21:1157.
5. DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131-I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999;40:1317.
6. 131I-tositumomab therapy of previously-untreated lymphoma patients. J Nucl Med 2003;44:457.
7. 131I-anti-B1 antibody: Assessment of tumor-dose response. J Nucl Med 2003;44:260.
8. Stabin M. Nuclear medicine dosimetry. Phys Med Biol 2006;51:R187.
9. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum tolerated dose, toxicity, and efficacy of 131-I-Lym-l antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
10. Hindorf C, Linden O, Stenberg L, et al. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 2003;9:4003s.
11. Hartman Siantar CL. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 2003;44:1322.
12. Prideaux A, Song H, Hobbs R, et al. Three-dimensional ra-diobiologic dosimetry: Application of radiobiologic modeling to patient specific three-dimensional-imaging-based internal dosimetry. J Nucl Med 2007;48:1008.
13. Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131-I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2005;32:458.
14. Wilderman SJ, Dewaraja YK. Method for fast CT/SPECT-based 3D Monte Carlo absorbed-dose computations in internal emitter therapy. IEEE Trans Nucl Sci 2007;54:146.
15. Roberson P, Amro H, Wilderman SJ, et al. Equivalent uniform dose calculation for 1-131 tositumomab therapy using SPECT/CT integrated imaging. J Nucl Med 2008;49:47P.
16. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974.
17. Stamm G, Nagel HD. CT Expoa novel program for dose evaluation in CT [in German], RoFo: Fortschritte auf der Rontgenstrahlen und der Nuklearmedizin 2002;174:1570.
18. Koral KF, Yendiki A, Qiang Lin, et al. Comparison of 3D OSEM versus ID SAGE for focal total-activity quantification in 1-131 SPECT with HE collimation. IEEE Trans Nucl Sci 2005;52;154.
19. Koral KF, Zasadny KR, Ackermann RJ, et al. Deadtime correction for two multihead Anger cameras in 131-1 dual-energy-window-acquisition mode. Med Phys 1998;25:85.
20. Dewaraja YK, Ljungberg M, Koral KF. Effects of dead time and pile up on quantitative SPECT for 1-131 dosimetric studies. J Nucl Med 2008;49:47P.
21. Dewaraja YK, Ljungberg M, Fessler JA. 3D Monte Carlo-based scatter compensation in quantitative 1-131 SPECT reconstruction. IEEE Trans Nucl Sci 2006;53:181.
22. Koral K, Yendiki A, Dewaraja YK. Recovery of total 1-131 activity within focal volumes using SPECT and 3D OSEM. Phys Med Biol 2007;52:777.
23. Shen S, DeNardo GL, O'Donnell RT, et al. Practical simplifications for dosimetric models for radioimmunotherapy. Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, May 1996.
24. Sempau J, Wilderman SJ, Bielajew AF. DPM a fast, accurate Monte Carlo code optimized for photon and electron radiotherapy treatment-planning dose computations. Phys Med Biol 2000;45:2262.
25. International Commission on Radiation Units and Measurements. Report 46: Photon, electron, proton, and neutron interaction data for body tissues. Bethesda, MD:ICRU, 1992.
26. Dewaraja YK, Wilderman SJ. Patient-specific dosimetry in radionuclide therapy: Effect of CT/SPECT misregistration and limited SPECT field of view. J Nucl Med 2005;46:89P.
27. Johnson TK, Colby SB. Photon contribution to tumor dose from considerations of 131-1 radiolabeled antibody uptake in liver, spleen, and whole body. Med Phys 1993;20:1667.
28. Davis T, Kaminski M, Leonard J, et al. The Radioisotope contributes significantly to the activity of radioimmuno-therapy. Clin Cancer Res 2004;10:7792.
29. Sisson, JC, Avram, AM, Lawson SA, et al. The so-called stunning of thyroid tissue. J Nucl Med 2006;47:1406.
30. Dewaraja YK, Wilderman SJ, Ljungberg M, et al. Accurate dosimetry in 1-131 radionuclide therapy using patient specific, three-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 2005;46:840.